SUMMARY In a prospective longitudinal study 130 patients with systemic lupus erythematosus (SLE) were studied at least monthly for a relationship between the anti-dsDNA levels and disease activity. We observed 13 patients who developed 15 periods of exacerbations of their disease. All 15 exacerbations were preceded by a continuous increase of the anti-dsDNA levels. In 13 of the 15 exacerbations studied the exacerbation was preceded by an increase of anti-dsDNA with a doubling time (T2) of less than 6 weeks; in 4 of the 5 other exacerbations the T2 was less than 10 weeks. Four other patients with an increase of the anti-dsDNA levels showed no exacerbation. In these 4 patients the T2 was larger than 10 weeks. The other 1 13 patients did not show an increase of anti-dsDNA over the 2 years of monitoring and showed no signs of serious disease activity (no major symptoms). These observations suggest that an SLE patient who is followed up frequently and who shows a continuous increase of anti-dsDNA with a T2 shorter than 10 weeks is bound to develop an exacerbation.
With the proper assay systems the diagnostic value of antibodies to double-stranded (ds)DNA seems to be beyond doubt.' Antibodies to dsDNA are found in high frequency in the serum of patients with active systemic lupus erythematosus2 (SLE) but not in the serum of normal persons and patients with a variety of other autoimmune diseases, such as discoid lupus erythematosus,3 chronic hepatitis,4 or rheumatoid arthritis.5 6 A more difficult problem is the relation between the anti-dsDNA level and disease activity. Systematic longitudinal studies are scarce and suffer from inadequate quantitation of anti-dsDNA and infrequent serum sampling. This might be the reason why no conclusion has yet emerged about the relation of anti-dsDNA level to disease activity. The only consistent finding is that patients with a persistently high anti-dsDNA level are bound to develop a major flare-up of the disease more frequently than patients with a low level.7
By thorough quantitation of anti-dsDNA and frequent serum sampling one can find a strict relationship between anti-dsDNA levels and disease activity.10 "' In a group of 43 SLE patients major symptoms of disease occurred only during a rapid decrease of the anti-dsDNA level. It A major drawback of that study was its retrospective character. Most patients entered the study at a time at which therapy had already been started. Moreover, the period preceding an exacerbation could not be analysed properly.
We here describe the result of a prospective longitudinal study of 130 SLE patients on the precise relation between anti-dsDNA levels and the occurrence of exacerbations, with emphasis on the period preceding the exacerbation. Prognostic value ofanti-dsDNA in SLE 389 highest anti-dsDNA were assembled. This point coincided within a week with the occurrence or presence of the exacerbation (major symptoms). Note that the anti-dsDNA levels are on log scale. It should be noted that a continuous plateau level was never obtained. After the anaemia a leucocytopenia and thrombocytopenia developed. According to the criteria of disease activity the start of the exacerbation took place on 18 August (anti-dsDNA level at that moment amounted to 5210 units/ml). Signs of deterioration of renal function were detected for the first time on 25 August (anti-dsDNA: 2672 units/ml). A slight but persistent proteinuria (about 1 g/24 h) was found; urine analysis showed the presence of erythrocytes, leucocytes, and hyaline cylinders. In the period from 16 to 25 August the creatinine level increased from 72 to 90 ,umol/l. On 1 September prednisolone was increased to 30 mg/day. Because of the patient's severe disease activity (deterioration of renat function, anaemia, leucocytopenia, and thrombocytopenia), prednisolone was raised to 60 mg/day and she was started on 75 mg azathioprine. This was followed by improvement, mainly of the renal function; however, the patient died on 27 September (sepsis). Histopathological examination of the kidney showed a focal-local glomerulonephritis.
Such a pattern of rise and fall of anti-dsDNA was found to accompany all 15 exacerbations (Fig. 3) . Therefore on the basis of these observations 2 questions are posed. Does a rising anti-dsDNA level herald a major exacerbation? And is the decrease in anti-dsDNA level seen after the onset of the exacerbation the result of therapy, or is it related to the cause of the exacerbation? RISING ANTI-DSDNA LEVEL HERALDS A MAJOR EXACERBATION All 15 exacerbations observed in these patients were preceded by an increasing serum anti-dsDNA level (Fig. 3) Fig. 7 Patients with a slow decrease ofanti-dsDNA levels. Anti-dsDNA levels decreased slowly in 7 patients. On clinical grounds it was impossible to differentiate these patients from the 106 patients with stable anti-dsDNA levels.
anti-ds DNA (units/ml) x 102 Fig. 8 Effect of therapy on anti-dsDNA levels. In patient B signs of renal involvement were diagnosed on 16 July 1976. The period from 3 to 17 July was characterised by decreasing anti-dsDNA levels. High-dose prednisolone was started on 22 July. proteinurla (grid) prednsolofl (mg/d) Wm7 after the onset of the decrease of anti-dsDNA. In the other 3 patients major symptoms started while antidsDNA was still increased, but within one week this was followed by a similar fast decrease of anti-dsDNA.
IS THE DECREASE OF ANTI-DSDNA A RESULT OF THERAPY?
In all 15 periods of an exacerbation a rapid decrease of the serum anti-dsDNA level took place. This raises the question whether this decrease is related to the pathogenesis of the lesions or whether it is an epiphenomenon. Therefore, it would be interesting to know whether this decrease is influenced by therapy. Here we encounter a serious problem. Generally, therapy is started the moment an exacerbation becomes manifest. As this is the very same moment when the anti-DNA level starts to fall, this does not allow a conclusion about the mechanism.
However, in this group of 13 patients there were 3 observations in which therapy was started rather late after the onset of the exacerbation. In all 3 cases anti-DNA levels were already decreasing when therapy was being given, and in none of the 3 cases was a clear effect seen on the rate of the decrease (Fig. 8) . This suggests that the drop in anti-DNA levels is related to the disease process rather than to therapy.
Discussion
Earlier studies'1 16 have shown that in SLE a better insight into the relationship between anti-dsDNA levels and disease activity was obtained by expressing the amount of anti-dsDNA antibodies in units/ml. In the present paper we describe a clear-cut relationship between anti-dsDNA profiles and disease activity in patients with SLE. Out of 130 patients studied 13 developed 15 periods with major clinical symptoms of their disease. All observed periods of major symptoms were heralded by a period with an increasing level of anti-dsDNA, whereas, concomitant with the development of major clinical symptoms antidsDNA levels decreased rapidly. Some questions are prompted on the basis of these observations:
(1) Can anti-dsDNA levels be used for prognostic purposes? (2) Is the drop in anti-dsDNA related to the pathogenesis of the disease? All 14 periods with an increasing level of antidsDNA, characterised by a doubling time under 10 weeks, developed major symptoms. In 13 cases the doubling time was 6 weeks or less. Although we feel that we have to enlarge the number of such observations, they strongly suggest that once a patient shows such a fast increase in the serum anti-dsDNA level, the patient is bound to develop an exacerbation.
The relationship between an exacerbation (major symptoms) and the drop in anti-dsDNA level is clear. In 14 patients the T' of serum anti-dsDNA was less than 2 weeks. In view of the normal T' of Ig, we might conclude that this decrease is due to complexation of anti-dsDNA to its antigen. This suggests that immunosuppressive therapy cannot be the explanation for this observation. This notion is enforced by the finding in 3 patients that the rate of decrease is not clearly influenced by prednisolone therapy. This leaves us with the question whether the complexation of anti-dsDNA is the cause of the exacerbation or the result of it. We do not feel that the present study allows us to draw conclusions on this part.
Although others have published similar results as ours, most investigators claim that anti-dsDNA levels are not very well correlated with disease activity.7`9 The reasons for this discrepancy are probably the following. (a) Our method of measuring anti-dsDNA (using circular dsDNA and no incubation at 4°C) selects for high-avidity antibodies."7 (b) Our data could be obtained only by titrating the sera, which is not done by most investigators. (c) The pattern of anti-dsDNA levels requires very frequent serum sampling. With this in mind we feel that most of the published data fit in our concept.
Although the selection of our patients was probably biased in terms of positivity in the Farr assay and in terms of renal involvement, it is remarkable that none of the 130 patients underwent a major exacerbation without a changing level of anti-dsDNA. It must be realised, however, that absolute values of anti-dsDNA varied from patient to patient.
It is also clear that a number of patients show a more or less constant high level of anti-dsDNA for years without showing major signs of disease. Why they do not develop an exacerbation remains speculative.
The conclusion of this study is that, when SLE patients are monitored frequently for anti-dsDNA, exacerbations can be foreseen. As a consequence it is possible that immunosuppressive therapy can be guided by the anti-dsDNA levels. When this therapy is started in the phase of increasing anti-dsDNA levels, we might be able to normalise anti-dsDNA before the exacerbation takes place. Another conclusion from our work must be that an isolated determination of anti-dsDNA can be used for diagnostic purposes"1 but not as a measure of disease activity.
For this purpose frequent serum sampling is necessary.
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